The Week Ahead In Biotech: Virtual Conference Presentations, Clovis PDUFA Date In The Spotlight

The smid-cap biotech earnings deluge hit Wall Street in the week ended May 9, positively impacting the stocks in the sector. The iShares NASDAQ Biotechnology Index (NASDAQ:IBB) gained about 6% for the week.

Large-cap pharma names AstraZeneca plc (NYSE:AZN) and Novartis AG (NYSE:NVS) received FDA nods for their heart failure and lung cancer therapies, respectively. After receiving emergency use authorization from the FDA in the U.S., Gilead Sciences, Inc.'s (NASDAQ:GILD) remdesivir obtained full regulatory approval in Japan.

Moderna Inc (NASDAQ:MRNA) received the OK to proceed with the Phase 2 trial of its mRNA coronavirus vaccine candidate mRNA-1273.

The following are the key events and catalysts that biotech investors need to watch in the coming week.

Conferences

Bank of America Securities 2020 HealthCare Virtual Conference: May 12-14
American Society of Gene and Cell Therapy, or ASGCT, 23rd Virtual Annual Meeting: May 12-15
2020 Society for Investigative Dermatology, or SID, Annual Meeting Virtual Conference: May 13-16
Society for Cardiovascular Angiography and Interventions, or SCAI, 2020 Virtual Conference, Scientific Sessions: May 14-16

PDUFA Dates

Clovis Oncology Inc (NASDAQ:CLVS) awaits the FDA nod for an expanded indication for its cancer therapy Rubraca. The sNDA seeks approval of Rubraca as a monotherapy treatment for patients with BRCA1/2-mutant recurrent, metastatic castrate-resistant prostate cancer.

Clinical Readouts

ASGCT Conference Presentations

Abeona Therapeutics Inc (NASDAQ:ABEO) is due to present updated interim results from the Transpher A and Transpher B studies, Phase 1/2 trials of ABO-102 and ABO-101, respectively, in mucopolysaccharidosis type IIIA, aka as Sanfilippo syndrome type.

Rocket Pharmaceuticals Inc (NASDAQ: RCKT will present updated data from Phase 1/2 FANCOLEN-I study, which is evaluating the safety and efficacy of infusion of autologous CD34 + cells transduced with a lentiviral vector carrying the FANCA gene in patients with Fanconi anemia subtype A, and updates from the Phase 1 LAD-I study that is evaluating its investigational gene therapy RP-L201 to treat severe Leukocyte Adhesion Deficiency-I.

Avrobio Inc (NASDAQ:AVRO) is scheduled to make an oral presentation on new data from the Phase 2 trial of AVR-RD-01 for Fabry (Wednesday). The company will also make an oral presentation of new data from the collaborator-sponsored Phase 1/2 clinical trial of AVR-RD-04 in cystinosis. Another oral presentation on new data from a preclinical research program for a gene therapy for Pompe disease is also scheduled for Wednesday.

Ultragenyx Pharmaceutical Inc (NASDAQ:RARE) is due to present updated data from the first three cohorts of a Phase 1/2 study of DTX301 in treating ornithine transcarbamylase deficiency (Wednesday). The company will also present updated data from the confirmatory cohort from a Phase 1/2 study of DTX401 in glycogen storage disease Type 1a (Friday).

Conferences

PDUFA Dates

Clinical Readouts

ASGCT Conference Presentations

Other Readouts

Earnings

IPO Quiet Period Expiry

Comments